Sara Tolaney

106PUBLICATIONS
571CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (106)

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Jun 05, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

|May 15, 2026
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

|May 13, 2026
Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.

|Mar 23, 2026
The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Jessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen

|Feb 27, 2026
The landscape of the intestinal microbiome among patients with newly diagnosed invasive breast cancer and ductal carcinoma in situ (DCIS).

Sarah L Sammons, Thomas M Kuntz, Molly DiLullo

Pageof 18

Frequent Collaborators

17 joint publications

Paolo Tarantino

17 joint publications

Ann Partridge

15 joint publications

Hope S Rugo

15 joint publications

Nabihah Tayob